Determination of Clonal Origin of Recurrent Hepatocellular Carcinoma for Personalized Therapy and Outcomes Evaluation: A New Strategy for Hepatic Surgery

Wang, Bin; Xia, Chunyan; Lau, W. Y.; Lu, Xinyuan; Dong, Hui; Yu, Wenlong; Jin, Guang‐Zhi; Wang, Cong; Wu, Mengchao

doi:10.1016/j.jamcollsurg.2013.07.402

Cited by 58 publications

(54 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have reported an IM-type recurrence of HCC after 8 years of the first surgery by detecting microsatellite alterations [40], indicating that residual cancer cells can become long-term latency within the "soil organs" in a "hibernation" status and can recover and grow into metastatic tumors under appropriate conditions. Moreover, it is generally considered that the dysplastic nodules occurring on the background of cirrhosis with random integration of HBV DNA may constitute the base of multicentric occurrence of HCC [41]. In addition, some scholars have proposed the histological standards for discriminating between IM-type and MO-type RHCCs [42].…”

Section: Determination Of the Clonality Of Rhcc And Multinodular Hccmentioning

confidence: 99%

New insights into molecular diagnostic pathology of primary liver cancer: Advances and challenges

Wang

2015

Cancer Letters

Self Cite

View full text Add to dashboard Cite

Section: Determination Of the Clonality Of Rhcc And Multinodular Hccmentioning

confidence: 99%

New insights into molecular diagnostic pathology of primary liver cancer: Advances and challenges

Wang

2015

Cancer Letters

Self Cite

View full text Add to dashboard Cite

“…Among all the patients, the percentage of IM type RHCC and MO type RHCC was 76.7% and 23.3%, respectively. MO type RHCC had a better prognosis than IM type RHCC (OS 130.8 ± 8.5 months vs. 80.8 ± 8.5 months; RFS 33.8 ± 4.5 months vs. 14.2 ± 2.5 months) [33] . Then, we classified 2 clonal patterns into 6 subclonal types: type I, single-nodular MO-RHCC; type II, single-nodular IM-RHCC; type III, singlenodular IM-RHCC spreading intrahepatic metastasis; type IV, multinodular MO-RHCC; type V, singlenodular MO-RHCC spreading intrahepatic metastasis; and type VI, single-nodular MO-RHCC combined with IM-RHCC [ Figure 3].…”

Section: The Clonal Origin Of Rhccmentioning

confidence: 90%

“…For example, heterogeneous clonal origin in single nodule HCC and IM-MO mixed clonal origin in RHCC and MHCC [30][31][32] . HCC with different clonal origin may engender variant clinical prognosis and therefore, different therapy method [33,34] . Consequently, it is a crucial cooperation for hepatic surgery and molecular pathology to formulate rational treatment strategy for RHCC and MHCC with different clonal origin.…”

Section: The Clonal Origin Of Hccmentioning

confidence: 99%

“…Some scholars has compared various kinds of methods [80,81] . According to our experience, we recommended the microsatellite LOH detection [33,82,83] . It is not only suitable for paraffin embedded tissues, resolves the restriction of gender and HBV infection, but also it can select a set of microsatellite profile to improve the diagnostic accuracy.…”

Section: Techniques Of Clonal Origin Detectionmentioning

confidence: 99%

See 1 more Smart Citation

New strategy to distinguish clonal origin of RHCC/MHCC between intrahepatic metastasis and multicentric occurrence

Wang¹,

Cong²

2018

Self Cite

View full text Add to dashboard Cite

have a poorer prognosis compared with those with MO type HCC. Therefore, it is essential to emphasize the distribution of the clonal origin in HCC in order to determine the choice of clinical treatment. Undoubtedly, the detection of clonal origin pattern will become a promising breakthrough in the molecular pathological diagnosis of HCC. We should attach more attention to the establishment of a standardized molecular pathological clonal origin detection method and a new stratification of clinical treatment choice for RHCC/MHCC in future.

show abstract

“…Loss of heterozygosity (LOH) is a non-random allelic loss of specific chromosomal loci, and it is closely associated with silencing of known or unknown tumor suppressor genes. Our previous research indicated that LOH detection has technical advantages for clonal discrimination in recurrent HCC [15] and hepatic carcinosarcoma [16]. …”

Section: Introductionmentioning

confidence: 99%

Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study

Zhao

et al. 2016

Chin J Cancer

Self Cite

View full text Add to dashboard Cite

BackgroundCombined hepatocellular and cholangiocarcinoma (CHC) is a unique subtype of liver cancer comprising both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC); however, its cellular origin remains unclear. The purpose of this study was to investigate the clinicopathologic features and the clonal relationship between HCC and ICC in 34 patients with CHC.MethodsThe clinicopathologic features and prognosis of the 34 CHC patients were compared with those of 29 patients with separated HCC and ICC (SHC). Loss of heterozygosity (LOH) at 10 highly polymorphic microsatellite markers was detected in 16 CHC and 10 SHC tissues for determination of the clonal origin of CHC. Expression of hepatocyte markers [hepatocyte paraffin 1 (Hep Par 1) and glypican 3 (GPC3)] and cholangiocyte markers [cytokeratin (CK)7 and 19] in tumor tissues was examined by immuno histochemical analysis.ResultsIn the 16 CHC specimens, the difference in LOH patterns between HCC and ICC was less than 30%, suggesting the same clonal origin of HCC and ICC. Consistent with this finding, immunohistochemical analysis revealed that hepatocyte markers (Hep Par 1 and GPC3) and cholangiocyte markers (CK7 and CK19) were simultaneously expressed in both the HCC and ICC components in 52.9% of CHC specimens, suggesting that the two components shared a similar phenotype with hepatic progenitor cells (HPCs). On the contrary, in all 10 SHC cases, the difference in LOH patterns between the HCC and ICC components was greater than 30%, suggesting different clonal origins of HCC and ICC. Overall survival and disease-free survival were shorter for patients with CHC than for patients with SHC (P < 0.05).ConclusionsOur results suggest that the HCC and ICC components of CHC may originate from the same clone, having the potential for dual-directional differentiation similar to HPCs. CHC tended to exhibit the biological behaviors of both HCC and ICC, which may enhance the infiltrative capacity of tumor cells, leading to poor clinical outcomes for patients with CHC.

show abstract

Determination of Clonal Origin of Recurrent Hepatocellular Carcinoma for Personalized Therapy and Outcomes Evaluation: A New Strategy for Hepatic Surgery

Cited by 58 publications

References 30 publications

New insights into molecular diagnostic pathology of primary liver cancer: Advances and challenges

New insights into molecular diagnostic pathology of primary liver cancer: Advances and challenges

New strategy to distinguish clonal origin of RHCC/MHCC between intrahepatic metastasis and multicentric occurrence

Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study

Contact Info

Product

Resources

About